# Marianna Fontana

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6813898/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 124 papers | 13,984 citations | 23567 58 h-index | 22166 113 g-index |

| | | | |
|---|---|---|---|
| 124 all docs | 124 docs citations | 124 times ranked | 9311 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Distinct cardiovascular phenotypes are associated with prognosis in systemic sclerosis: a cardiovascular magnetic resonance study. European Heart Journal Cardiovascular Imaging, 2023, 24, 463-471. | 1.2 | 7 |
| 2 | Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy. Heart, 2022, 108, 474-478. | 2.9 | 8 |
| 3 | Clinical Importance of Left Atrial Infiltration in Cardiac TransthyretinÂAmyloidosis. JACC: Cardiovascular Imaging, 2022, 15, 17-29. | 5.3 | 67 |
| 4 | Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis. European Heart Journal, 2022, 43, 333-341. | 2.2 | 45 |
| 5 | Impact of afterload and infiltration on coexisting aortic stenosis and transthyretin amyloidosis. Heart, 2022, 108, 67-72. | 2.9 | 8 |
| 6 | The role of serial <sup>99m</sup>Tc-DPD scintigraphy in monitoring cardiac transthyretin amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 38-49. | 3.0 | 8 |
| 7 | Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature, 2022, 601, 110-117. | 27.8 | 280 |
| 8 | Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science, 2022, 375, 183-192. | 12.6 | 91 |
| 9 | Quantitative Myocardial Perfusion Predicts Outcomes in Patients With Prior SurgicalÂRevascularization. Journal of the American College of Cardiology, 2022, 79, 1141-1151. | 2.8 | 10 |
| 10 | HLAâ€DR polymorphism in SARSâ€CoVâ€2 infection and susceptibility to symptomatic COVIDâ€19. Immunology, 2022, 166, 68-77. | 4.4 | 18 |
| 11 | RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nature Reviews Cardiology, 2022, 19, 655-667. | 13.7 | 64 |
| 12 | Critical Comparison of Documents FromÂScientific Societies on CardiacÂAmyloidosis. Journal of the American College of Cardiology, 2022, 79, 1288-1303. | 2.8 | 35 |
| 13 | Ongoing Exercise Intolerance Following COVIDâ€19: A Magnetic Resonanceâ€“Augmented Cardiopulmonary Exercise Test Study. Journal of the American Heart Association, 2022, 11, e024207. | 3.7 | 15 |
| 14 | Characteristics and natural history of early-stage cardiac transthyretin amyloidosis. European Heart Journal, 2022, 43, 2622-2632. | 2.2 | 27 |
| 15 | Imaging-Guided Treatment for Cardiac Amyloidosis. Current Cardiology Reports, 2022, 24, 839-850. | 2.9 | 13 |
| 16 | Comparison of 99mTc-DPD Scintigraphy, CMR Imaging, and Echocardiography in Patients With V30M-Associated Hereditary Transthyretin Amyloidosis. JACC: Cardiovascular Imaging, 2022, , . | 5.3 | 0 |
| 17 | Systemic embolism in amyloid transthyretin cardiomyopathy. European Journal of Heart Failure, 2022, 24, 1387-1396. | 7.1 | 23 |
| 18 | Immune boosting by B.1.1.529 ( Omicron) depends on previous SARS-CoV-2 exposure. Science, 2022, 377, . | 12.6 | 241 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression. JACC: Cardiovascular Imaging, 2021, 14, 189-199. | 5.3 | 113 |
| 20 | Prevalence and Outcomes of Concomitant Aortic Stenosis and CardiacÂAmyloidosis. Journal of the American College of Cardiology, 2021, 77, 128-139. | 2.8 | 187 |
| 21 | A simple echocardiographic score to rule out cardiac amyloidosis. European Journal of Clinical Investigation, 2021, 51, e13449. | 3.4 | 24 |
| 22 | Quantitative cardiovascular magnetic resonance myocardial perfusion mapping to assess hyperaemic response to adenosine stress. European Heart Journal Cardiovascular Imaging, 2021, 22, 273-281. | 1.2 | 15 |
| 23 | Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. European Heart Journal, 2021, 42, 1866-1878. | 2.2 | 274 |
| 24 | A review of the criteria for non-invasive diagnosis of cardiac transthyretin amyloidosis. Expert Opinion on Orphan Drugs, 2021, 9, 87-94. | 0.8 | 2 |
| 25 | Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARSâ€‘CoV-2 infection. EBioMedicine, 2021, 65, 103259. | 6.1 | 61 |
| 26 | Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2021, 42, 1554-1568. | 2.2 | 434 |
| 27 | Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology <scp>W</scp>orking <scp>G</scp>roup on <scp>M</scp>yocardial and <scp>P</scp>ericardial <scp>D</scp>iseases. European Journal of Heart Failure, 2021, 23, 512-526. | 7.1 | 153 |
| 28 | Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science, 2021, 372, 1418-1423. | 12.6 | 286 |
| 29 | The Authors Reply:. JACC: Cardiovascular Imaging, 2021, 14, 882-883. | 5.3 | 0 |
| 30 | Cardiac Magnetic Resonanceâ€“Derived Extracellular Volume Mapping for the Quantification of Hepatic and Splenic Amyloid. Circulation: Cardiovascular Imaging, 2021, 14, CIRCIMAGING121012506. | 2.6 | 19 |
| 31 | Splenic regression of amyloid on multi-modality imaging in response to treatment with patisiran and diflunisal in hereditary transthyretin amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 269-270. | 3.0 | 1 |
| 32 | CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. New England Journal of Medicine, 2021, 385, 493-502. | 27.0 | 807 |
| 33 | The evolution of cardiovascular COVID-19 research. European Heart Journal, 2021, 42, 2953-2954. | 2.2 | 2 |
| 34 | Cardiac Amyloidosis: Multimodal Imaging of Disease Activity and Response to Treatment. Circulation: Cardiovascular Imaging, 2021, 14, e009025. | 2.6 | 24 |
| 35 | ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€”Evidence Base and Standardized Methods of Imaging. Circulation: Cardiovascular Imaging, 2021, 14, e000029. | 2.6 | 48 |
| 36 | ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€”Diagnostic Criteria and Appropriate Utilization. Circulation: Cardiovascular Imaging, 2021, 14, e000030. | 2.6 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | 99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis. European Heart Journal Cardiovascular Imaging, 2021, 22, 1304-1311. | 1.2 | 26 |
| 38 | Advances in Diagnosis and Treatment of Cardiac and Renal Amyloidosis. Cardiology Clinics, 2021, 39, 389-402. | 2.2 | 7 |
| 39 | Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: a nested, case-control diagnostic accuracy study. Lancet Microbe, The, 2021, 2, e508-e517. | 7.3 | 52 |
| 40 | The Authorsâ€™ Reply. JACC: Cardiovascular Imaging, 2021, 14, 2268-2269. | 5.3 | 1 |
| 41 | Bright-blood and dark-blood phase sensitive inversion recovery late gadolinium enhancement and T1 and T2 maps in a single free-breathing scan: an all-in-one approach. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 126. | 3.3 | 7 |
| 42 | Cardiovascular Magnetic Resonance Parametric Mapping Techniques: Clinical Applications and Limitations. Current Cardiology Reports, 2021, 23, 185. | 2.9 | 5 |
| 43 | Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science, 2021, , eabm0811. | 12.6 | 10 |
| 44 | Cardiac Amyloidosis: A Review of Current Imaging Techniques. Frontiers in Cardiovascular Medicine, 2021, 8, 751293. | 2.4 | 16 |
| 45 | Myocardial Perfusion Imaging After Severe COVID-19 Infection Demonstrates Regional Ischemia Rather Than Global Blood Flow Reduction. Frontiers in Cardiovascular Medicine, 2021, 8, 764599. | 2.4 | 9 |
| 46 | Noncontrast Magnetic Resonance for theÂDiagnosis of Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 69-80. | 5.3 | 125 |
| 47 | ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2â€”Diagnostic criteria and appropriate utilization. Journal of Nuclear Cardiology, 2020, 27, 659-673. | 2.1 | 97 |
| 48 | Multiparametric Echocardiography Scores for the Diagnosis of CardiacÂAmyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 909-920. | 5.3 | 136 |
| 49 | Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage. ESC Heart Failure, 2020, 7, 3942-3949. | 3.1 | 22 |
| 50 | COVID-19. Circulation, 2020, 142, 1120-1122. | 1.6 | 126 |
| 51 | The Authors Reply:. JACC: Cardiovascular Imaging, 2020, 13, 1294-1295. | 5.3 | 1 |
| 52 | Automated Inline Analysis of Myocardial Perfusion MRI with Deep Learning. Radiology: Artificial Intelligence, 2020, 2, e200009. | 5.8 | 32 |
| 53 | Diffusion Tensor Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation: Cardiovascular Imaging, 2020, 13, e009901. | 2.6 | 26 |
| 54 | Myocardial Edema, Myocyte Injury, and Disease Severity in Fabry Disease. Circulation: Cardiovascular Imaging, 2020, 13, e010171. | 2.6 | 35 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Diagnostic imaging of cardiac amyloidosis. Nature Reviews Cardiology, 2020, 17, 413-426. | 13.7 | 84 |
| 56 | The Prognostic Significance of Quantitative Myocardial Perfusion: An Artificial Intelligence Based Approach Using Perfusion Mapping. Circulation, 2020, 141, 1282-1291. | 1.6 | 100 |
| 57 | Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. European Heart Journal, 2020, 41, 1439-1447. | 2.2 | 108 |
| 58 | Analysis of Cardiac Amyloidosis Progression Using Model-Based Markers. Frontiers in Physiology, 2020, 11, 324. | 2.8 | 3 |
| 59 | Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathologyÂin patients referred for transcatheter aortic valve implantation. European Heart Journal, 2020, 41, 2759-2767. | 2.2 | 128 |
| 60 | Assessment of Multivessel Coronary Artery Disease Using Cardiovascular Magnetic Resonance Pixelwise Quantitative Perfusion Mapping. JACC: Cardiovascular Imaging, 2020, 13, 2546-2557. | 5.3 | 30 |
| 61 | Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Science Immunology, 2020, 5, . | 11.9 | 172 |
| 62 | Healthcare Workers Bioresource: Study outline and baseline characteristics of a prospective healthcare worker cohort to study immune protection and pathogenesis in COVID-19. Wellcome Open Research, 2020, 5, 179. | 1.8 | 10 |
| 63 | Healthcare Workers Bioresource: Study outline and baseline characteristics of a prospective healthcare worker cohort to study immune protection and pathogenesis in COVID-19. Wellcome Open Research, 2020, 5, 179. | 1.8 | 21 |
| 64 | Role of CMR Mapping Techniques in Cardiac Hypertrophic Phenotype. Diagnostics, 2020, 10, 770. | 2.6 | 19 |
| 65 | Detailed Understating of CardiacÂAmyloidosis by CMR. JACC: Cardiovascular Imaging, 2020, 13, 1311-1313. | 5.3 | 1 |
| 66 | Atrial Involvement in Cardiac Amyloidosis. JACC: CardioOncology, 2020, 2, 732-734. | 4.0 | 3 |
| 67 | Cardiac Amyloidosis: Updates in Imaging. Current Cardiology Reports, 2019, 21, 108. | 2.9 | 41 |
| 68 | Myocardial Amyloidosis. JACC: Cardiovascular Imaging, 2019, 12, 2345-2356. | 5.3 | 74 |
| 69 | ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2019, 26, 2065-2123. | 2.1 | 230 |
| 70 | Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circulation: Heart Failure, 2019, 12, e006075. | 3.9 | 312 |
| 71 | ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Journal of Cardiac Failure, 2019, 25, 854-865. | 1.7 | 70 |
| 72 | ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2019, 25, e1-e39. | 1.7 | 107 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Noninvasive Mapping of the Electrophysiological Substrate in Cardiac Amyloidosis and Its Relationship to Structural Abnormalities. Journal of the American Heart Association, 2019, 8, e012097. | 3.7 | 21 |
| 74 | The UK National Amyloidosis Centre. European Heart Journal, 2019, 40, 1661-1664. | 2.2 | 3 |
| 75 | Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation, 2019, 140, 16-26. | 1.6 | 288 |
| 76 | Treatment of cardiac transthyretin amyloidosis: an update. European Heart Journal, 2019, 40, 3699-3706. | 2.2 | 121 |
| 77 | High Prevalence of Intracardiac Thrombi in Cardiac Amyloidosis. Journal of the American College of Cardiology, 2019, 73, 1733-1734. | 2.8 | 65 |
| 78 | Acute changes in cardiac structural and tissue characterisation parameters following haemodialysis measured using cardiovascular magnetic resonance. Scientific Reports, 2019, 9, 1388. | 3.3 | 27 |
| 79 | Automated Pixel-Wise Quantitative Myocardial Perfusion Mapping by CMRÂtoÂDetect Obstructive Coronary Artery Disease and Coronary Microvascular Dysfunction. JACC: Cardiovascular Imaging, 2019, 12, 1958-1969. | 5.3 | 140 |
| 80 | A case report of eosinophilic granulomatosis and polyangiitis myocarditis presenting as ST elevation myocardial infarction and showing positive response to immunotherapy. European Heart Journal - Case Reports, 2019, 3, 1-6. | 0.6 | 3 |
| 81 | Relative Left Ventricular Apical Sparing of Longitudinal Strain in Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2019, 12, 1174-1176. | 5.3 | 23 |
| 82 | Native T1 and Extracellular Volume inÂTransthyretin Amyloidosis. JACC: Cardiovascular Imaging, 2019, 12, 810-819. | 5.3 | 172 |
| 83 | Cardiac Structural and Functional Consequences of Amyloid Deposition byÂCardiac Magnetic Resonance andÂEchocardiography and TheirÂPrognosticÂRoles. JACC: Cardiovascular Imaging, 2019, 12, 823-833. | 5.3 | 113 |
| 84 | Reverse Myocardial Remodeling FollowingÂValve Replacement in PatientsÂWith Aortic Stenosis. Journal of the American College of Cardiology, 2018, 71, 860-871. | 2.8 | 266 |
| 85 | Prevalence of Cardiac Amyloidosis in Patients Referred for Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2018, 71, 463-464. | 2.8 | 111 |
| 86 | Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. Science Translational Medicine, 2018, 10, . | 12.4 | 94 |
| 87 | Cardiac amyloidosis. Clinical Medicine, 2018, 18, s30-s35. | 1.9 | 135 |
| 88 | CMR-Verified Regression of Cardiac AL Amyloid After Chemotherapy. JACC: Cardiovascular Imaging, 2018, 11, 152-154. | 5.3 | 90 |
| 89 | A new staging system for cardiac transthyretin amyloidosis. European Heart Journal, 2018, 39, 2799-2806. | 2.2 | 396 |
| 90 | Sex Dimorphism in the MyocardialÂResponse to Aortic Stenosis. JACC: Cardiovascular Imaging, 2018, 11, 962-973. | 5.3 | 85 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Extracellular volume with bolusâ€•only technique in amyloidosis patients: Diagnostic accuracy, correlation with other clinical cardiac measures, and ability to track changes in amyloid load over time. Journal of Magnetic Resonance Imaging, 2018, 47, 1677-1684. | 3.4 | 7 |
| 92 | Quantitation of <sup>99m</sup>Tc-DPD uptake in patients with transthyretin-related cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 203-210. | 3.0 | 42 |
| 93 | Reply. Journal of the American College of Cardiology, 2018, 72, 1881. | 2.8 | 2 |
| 94 | Therapies for cardiac light chain amyloidosis: An update. International Journal of Cardiology, 2018, 271, 152-160. | 1.7 | 31 |
| 95 | Myocardial Edema and Prognosis inÂAmyloidosis. Journal of the American College of Cardiology, 2018, 71, 2919-2931. | 2.8 | 145 |
| 96 | Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. European Heart Journal, 2017, 38, 1905-1908. | 2.2 | 144 |
| 97 | Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. European Heart Journal Cardiovascular Imaging, 2017, 18, 1344-1350. | 1.2 | 124 |
| 98 | Magnetic Resonance in TransthyretinÂCardiac Amyloidosis. Journal of the American College of Cardiology, 2017, 70, 466-477. | 2.8 | 290 |
| 99 | 001â€…Multiparametric mapping to understand pathophysiology in cardiac amyloidosis. Heart, 2017, 103, A1-A2. | 2.9 | 12 |
| 100 | 028â€…Routine identification of hypoperfusion in cardiac amyloidosis by myocardial blood flow mapping. Heart, 2017, 103, A24-A24. | 2.9 | 3 |
| 101 | A case report in cardiovascular magnetic resonance: the contrast agent matters in amyloid. BMC Medical Imaging, 2017, 17, 3. | 2.7 | 9 |
| 102 | Prognosis in Cardiac Amyloidosis by LGE. JACC: Cardiovascular Imaging, 2016, 9, 687-689. | 5.3 | 4 |
| 103 | Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation, 2016, 133, 2404-2412. | 1.6 | 1,335 |
| 104 | Staging Cardiac Amyloidosis With CMR. JACC: Cardiovascular Imaging, 2016, 9, 1278-1279. | 5.3 | 10 |
| 105 | Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis. Circulation: Cardiovascular Imaging, 2016, 9, . | 2.6 | 210 |
| 106 | Automatic Measurement of the MyocardialÂInterstitium. JACC: Cardiovascular Imaging, 2016, 9, 54-63. | 5.3 | 127 |
| 107 | Dark blood late enhancement imaging. Journal of Cardiovascular Magnetic Resonance, 2016, 18, 77. | 3.3 | 64 |
| 108 | Prospective comparison of novel dark blood late gadolinium enhancement with conventional bright blood imaging for the detection of scar. Journal of Cardiovascular Magnetic Resonance, 2016, 19, 91. | 3.3 | 36 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | T1 mapping and T2 mapping at 3T for quantifying the area-at-risk in reperfused STEMI patients. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 73. | 3.3 | 70 |
| 110 | T1 mapping and survival in systemic light-chain amyloidosis. European Heart Journal, 2015, 36, 244-251. | 2.2 | 310 |
| 111 | Cardiovascular magnetic resonance for amyloidosis. Heart Failure Reviews, 2015, 20, 133-144. | 3.9 | 120 |
| 112 | Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study. Radiology, 2015, 277, 388-397. | 7.3 | 146 |
| 113 | Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. New England Journal of Medicine, 2015, 373, 1106-1114. | 27.0 | 304 |
| 114 | Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation, 2015, 132, 1570-1579. | 1.6 | 442 |
| 115 | Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2014, 16, 99. | 3.3 | 154 |
| 116 | Native T1 Mapping in Transthyretin Amyloidosis. JACC: Cardiovascular Imaging, 2014, 7, 157-165. | 5.3 | 339 |
| 117 | AL and ATTR cardiac amyloid are different: native T1 mapping and ECV detect different biology. Journal of Cardiovascular Magnetic Resonance, 2014, 16, P341. | 3.3 | 11 |
| 118 | Native T1 mapping in ATTR cardiac amyloidosis - comparison with AL cardiac amyloidosis - a 200 patient study. Journal of Cardiovascular Magnetic Resonance, 2014, 16, O4. | 3.3 | 2 |
| 119 | T1 Mapping for Characterization of Intracellular and Extracellular Myocardial Diseases in Heart Failure. Current Cardiovascular Imaging Reports, 2014, 7, 9287. | 0.6 | 37 |
| 120 | Noncontrast T1 Mapping for the Diagnosis of Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2013, 6, 488-497. | 5.3 | 517 |
| 121 | T1 Mapping for Myocardial Extracellular Volume Measurement by CMR. JACC: Cardiovascular Imaging, 2013, 6, 955-962. | 5.3 | 245 |
| 122 | Identification and Assessment of Anderson-Fabry Disease by Cardiovascular Magnetic Resonance Noncontrast Myocardial T1 Mapping. Circulation: Cardiovascular Imaging, 2013, 6, 392-398. | 2.6 | 399 |
| 123 | Quantification of Myocardial Extracellular Volume Fraction in Systemic AL Amyloidosis. Circulation: Cardiovascular Imaging, 2013, 6, 34-39. | 2.6 | 261 |
| 124 | Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 87. | 3.3 | 207 |